Literature DB >> 7048646

Minocycline.

M Jonas, B A Cunha.   

Abstract

Minocycline, a second generation tetracycline derivative, was first introduced in 1967. The following review considers the physiochemical and pharmacokinetic properties, antimicrobial activity, clinical uses, and adverse effects of minocycline. Excellent tissue and secretion penetration due to its higher lipid solubility, good broad spectrum activity, superior gastrointestinal absorption, decreased alteration of the fecal flora, and prolonged half-life, are properties that make minocycline a unique antimicrobial agent. Despite these exceptional characteristics, minocycline remains an infrequently used agent because of the availability of alternate drugs and the vestibular dysfunction associated with its administration.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7048646

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  19 in total

1.  Does minocycline, an antibiotic with inhibitory effects on microglial activation, sharpen a sense of trust in social interaction?

Authors:  Motoki Watabe; Takahiro A Kato; Akira Monji; Hideki Horikawa; Shigenobu Kanba
Journal:  Psychopharmacology (Berl)       Date:  2011-09-29       Impact factor: 4.530

Review 2.  Pharmacological therapies for Angelman syndrome.

Authors:  Wen-Hann Tan; Lynne M Bird
Journal:  Wien Med Wochenschr       Date:  2016-01-12

3.  Minocycline reduced craving for cigarettes but did not affect smoking or intravenous nicotine responses in humans.

Authors:  Mehmet Sofuoglu; Andrew J Waters; Marc Mooney; Stephanie S O'Malley
Journal:  Pharmacol Biochem Behav       Date:  2008-11-13       Impact factor: 3.533

Review 4.  Topical antimicrobials for burn infections - an update.

Authors:  Mert Sevgi; Ani Toklu; Daniela Vecchio; Michael R Hamblin
Journal:  Recent Pat Antiinfect Drug Discov       Date:  2013-12

Review 5.  Clinical pharmacokinetics of doxycycline and minocycline.

Authors:  S Saivin; G Houin
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

6.  Case Series: Minocycline-Associated Thyroiditis.

Authors:  Kate Millington; Alexandra Charrow; Jessica Smith
Journal:  Horm Res Paediatr       Date:  2019-09-18       Impact factor: 2.852

7.  Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures.

Authors:  Agustini Utari; Weerasak Chonchaiya; Susan M Rivera; Andrea Schneider; Randi J Hagerman; Sultana M H Faradz; Iryna M Ethell; Danh V Nguyen
Journal:  Am J Intellect Dev Disabil       Date:  2010-09

Review 8.  Similarities and differences between doxycycline and minocycline: clinical and antimicrobial stewardship considerations.

Authors:  B A Cunha; J Baron; C B Cunha
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-08-17       Impact factor: 3.267

9.  Minocycline modulates neuroinflammation independently of its antimicrobial activity in staphylococcus aureus-induced brain abscess.

Authors:  Tammy Kielian; Nilufer Esen; Shuliang Liu; Nirmal K Phulwani; Mohsin M Syed; Napoleon Phillips; Koren Nishina; Ambrose L Cheung; Joseph D Schwartzman; Jorg J Ruhe
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

10.  Minocycline and N-methyl-4-isoleucine cyclosporin (NIM811) mitigate storage/reperfusion injury after rat liver transplantation through suppression of the mitochondrial permeability transition.

Authors:  Tom P Theruvath; Zhi Zhong; Peter Pediaditakis; Venkat K Ramshesh; Robert T Currin; Andrey Tikunov; Ekhson Holmuhamedov; John J Lemasters
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.